Plain-English translation of NCT07029230 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are testing whether a blood marker called sST2 can help predict heart failure in children who have surgery to repair congenital heart defects. This marker has shown promise in adult heart surgery patients, but doctors don't yet know if it works the same way in children. This study will collect blood samples before, during, and after surgery to see if sST2 levels can tell doctors which children are at highest risk for future heart problems.
Many children survive congenital heart surgery but later develop serious heart complications like heart failure. Doctors need better tools to identify which children are at highest risk early on, so they can watch them more closely and treat them sooner if needed.
You likely qualify if…
You likely don't qualify if…
If you join this study, the research team will collect small blood samples at three time points: before your heart surgery, during the surgery, and after it. These samples will be tested to measure the sST2 marker. Doctors will also follow your health over time to see if the marker levels predicted any heart problems. The study is based at a single hospital center, and all information will be carefully recorded to ensure accuracy.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Switzerland
Sponsor
Martin Schweiger
Collaborators
University Children's Hospital, Zurich
Enrollment target
~225 participants
Started
September 2025
Primary completion
December 2027
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Martin Schweiger, Prof, MD, MBA
University Children's Hospital, Zurich
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.